MedTrace Logo

Subcutaneous Calcitonin in Acute Herpes Zoster

NCT07655804 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2026-07-06

No results posted yet for this study

Summary

This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.

Conditions

  • Calcitonin
  • Subcutaneous
  • Acute Herpes Zoster

Interventions

DRUG

Calcitonin

patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks

OTHER

Saline

patients will receive subcutaneous saline (1 ml) daily for three weeks.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-04-01
Completion
2027-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07655804 on ClinicalTrials.gov